New Medicine Delivery for Prostate Cancer
Molecular imaging of novel PARP inhibitor nanomedicine delivery
This project aims to create a new medicine and a special scan to better treat advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11125965 on NIH RePORTER |
What this research studies
Metastatic castration-resistant prostate cancer is a very serious disease that is currently incurable. While existing PARP inhibitor medicines have shown promise for some patients with specific genetic changes, we are developing a new 'nanomedicine' designed to deliver a PARP inhibitor more effectively to tumors. This new medicine is intended to enhance treatment while potentially reducing side effects. We are also creating a special imaging tool that works with the new medicine to help doctors see if the treatment is reaching the tumor as intended. This approach will first be tested in laboratory models and then in a small group of men with metastatic prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates would be men with metastatic castration-resistant prostate cancer, particularly those with certain genetic changes that respond to PARP inhibitors.
Not a fit: Patients whose prostate cancer does not have the specific genetic changes that respond to PARP inhibitors may not benefit from this particular treatment.
Why it matters
Potential benefit: If successful, this new approach could offer a more effective and safer treatment option for men with advanced prostate cancer.
How similar studies have performed: While PARP inhibitors have shown promise in some patients, this specific combination of a new nanomedicine and companion imaging tool is a novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Vanbrocklin, Henry F. — University of California, San Francisco
- Study coordinator: Vanbrocklin, Henry F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.